Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00077675 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)
A Phase 2 study of Infections, Gram-positive Bacterial, sponsored by Cumberland Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 201
- Enrollment target
- 1
- Study location
NCT00077675 is a Phase 2 study of Infections, Gram-positive Bacterial that has completed, run by Cumberland Pharmaceuticals. The registered enrollment target is 201 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00077675, a Phase 2 study of Infections, Gram-positive Bacterial, has completed, sponsored by Cumberland Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 201 participants
- Enrollment target
- 1
- Study location
Study Summary
Serious infections caused by resistant bacteria are becoming more of a medical problem throughout the world. This study will measure how well TD-6424 (Telavancin) can control infections and whether the drug is safe to give to patients.
Conditions Studied
Interventions
- DRUG Telavancin
- DRUG vancomycin or antistaphylococcal penicillin
Study Locations (1)
California
- Paradise Valley Hospital, 2400 E. 4th Street - National City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 201 participants |
| Start Date | 2004-02 |
| Est. Completion | 2004-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00077675
The ClinicalTrials.gov registry entry for NCT00077675 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 201 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cumberland Pharmaceuticals, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Infections, Gram-positive Bacterial appearing as the primary indexed condition, and to 2 interventions - of which Telavancin is the first listed.
NCT00077675 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00077675 about?
NCT00077675 is a clinical study titled "Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)". Serious infections caused by resistant bacteria are becoming more of a medical problem throughout the world. This study will measure how well TD-6424 (Telavancin) can control infections and whether the drug is safe to give to patients.
What is the current status of trial NCT00077675?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 201 participants. The study started on 2004-02. Estimated completion is 2004-09.
What conditions does trial NCT00077675 study?
This clinical trial studies the following conditions: Infections, Gram-positive Bacterial.
What interventions are being tested in trial NCT00077675?
The interventions under investigation include: Telavancin (DRUG), vancomycin or antistaphylococcal penicillin (DRUG).
Who is sponsoring clinical trial NCT00077675?
This trial is sponsored by Cumberland Pharmaceuticals, which has 43 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00077675 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Infections, Gram-positive Bacterial
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.